Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial

Abstract Background Anthracycline-containing neoadjuvant chemotherapy (NACT) is the standard treatment for early triple-negative breast cancer (eTNBC); however, it is associated with substantial toxicity. We performed whole transcriptome profiling of baseline tumor biopsies to identify gene networks...

全面介紹

書目詳細資料

Principais autores:	Darren Korbie, Clare Stirzaker, Oleg Gluz, Christine zu Eulenburg, Ulrike Nitz, Matthias Christgen, Sherko Kuemmel, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Claudia Schumacher, Rachel Wuerstlein, Enrico Pelz, Hans Heinrich Kreipe, Susan J. Clark, Matt Trau, Monika Graeser, Nadia Harbeck
格式:	Artigo
語言:	Inglês
出版:	BMC 2025-03-01
叢編:	Molecular Cancer
主題:	Neoadjuvant therapy Triple negative breast neoplasms Translational research Biomedical Gene regulatory networks Gene expression profiling
在線閱讀:	https://doi.org/10.1186/s12943-025-02275-0
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!